ASIA unversity:Item 310904400/6766
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 90429/105609 (86%)
造访人次 : 10283427      在线人数 : 82
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻
    ASIA unversity > 醫學暨健康學院 > 期刊論文 >  Item 310904400/6766


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://asiair.asia.edu.tw/ir/handle/310904400/6766


    题名: A Novel Strategy for Designing Dual-target Inhibitors of KU86 and XRCC4
    作者: Chien-Yu Chen;Fuu-Jen Tsai;Jing-Gung Chung;Chang-Hai Tsai;Yuan-Man Hsu;Hung-Jin Huang;Tin-Yun Ho;Yea-Huey Chang;Da-Tian Bau;Ming-Hsui Tsai;Chen, Calvin Yu-Chian
    日期: 2009-10
    上传时间: 2009-12-23 14:22:09 (UTC+8)
    出版者: Asia University
    摘要: This is the first time that we reported about dual target inhibitors of KU86 and XRCC4. XRCC4 was well known as the downstream of KU86-DNA complex. They both play an important role in the DNA double-strain breaks (DSBs) repair system subpathway, non-homologous end joining (NHEJ).In this study, The protocol of docking analysis was applied to find the specific compounds, which had highest affinities to KU86 and XRCC4, from our database. The docking results were analyzed by cross validation. From the results above, myricetin and xanthone series had quietly the same core structure. The different shapes of binding sites from the two proteins might be the major factor to different affinities from these three potent dual-target inhibitors. Our work provides a new strategy for developing dual-target anticancer drug, and may contribute to clinical anticancer drug discovery and application.
    關聯: IEEE/ACM Transactions on Computational Biology and Bioinformatics
    显示于类别:[醫學暨健康學院] 期刊論文

    文件中的档案:

    档案 大小格式浏览次数
    index.html0KbHTML166检视/开启


    在ASIAIR中所有的数据项都受到原著作权保护.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈